Sarosdy M F, Higdon A L, Demoor C A
Division of Urology, University of Texas Health Science Center at San Antonio 78284-7845, USA.
J Urol. 1996 Jun;155(6):2085-9.
To evaluate bropirimine for in vivo activity in rodent prostate cancer.
Subcutaneously injected PAIII and Dunning MAT-LyLu rodent prostate cancer cells caused solid tumors and death in controls. Bropirimine was given on varying schedules at 250 mg./kg. by gavage, and tumor volume and survival were recorded.
Bropirimine prevented growth when given on the day of tumor injection and caused 95% of advanced tumors to regress completely in the PAIII model. Bropirimine caused significant growth inhibition and prolongation of survival in the MAT-LyLu model.
Bropirimine has statistically significant in vivo activity against both of these rodent prostate cancer cell lines.
